Evolent Health (NYSE:EVH) Issues Earnings Results

Evolent Health (NYSE:EVH) announced its earnings results on Thursday. The technology company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35), Zacks reports. Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%.

Evolent Health Price Performance

Shares of NYSE:EVH traded up $0.19 on Thursday, reaching $10.71. 2,588,197 shares of the company were exchanged, compared to its average volume of 2,146,734. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a 1-year low of $9.45 and a 1-year high of $35.00. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -11.77 and a beta of 1.45. The company has a 50-day moving average of $10.79 and a 200-day moving average of $18.98.

Wall Street Analyst Weigh In

Several research firms recently commented on EVH. BTIG Research reduced their price target on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a research report on Wednesday, February 12th. Oppenheimer reduced their price target on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, January 24th. Canaccord Genuity Group reduced their price target on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, Stephens reduced their price target on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Evolent Health has a consensus rating of “Buy” and an average price target of $17.92.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.